

# Dubai Derma<sup>®</sup>

Skin Health is our Concern

23<sup>rd</sup> Dubai World Dermatology and  
Laser Conference & Exhibition

**Shaping the Future of  
Dermatology & Aesthetics**

**PRE-CONFERENCE COURSE**  
ON DERMATOLOGY and DERMATOPATHOLOGY

**2 – 5 March 2024**

Dubai World Trade Centre

Supported by



رابطة أطباء الجلدية العرب  
Pan Arab League of Dermatology



الهيئة الاتحادية للهوية والجنسية  
FEDERAL AUTHORITY FOR IDENTITY & CITIZENSHIP

Strategic Partner

Organized by





**His Highness Sheikh Mohamed bin Zayed Al Nahyan**  
President of the United Arab Emirates



**His Highness Sheikh Mohammed bin Rashid Al Maktoum**

Vice President and Prime Minister of the UAE and Ruler of Dubai

# TABLE OF CONTENT

Messages

Messages from the Conference Chairman ..... 5

Message from the Executive Chairman ..... 6

Speech from the AADA President ..... 7

Message from the Secretary General ..... 9

Scientific Committee ..... 11

Organising Committee ..... 13

Accreditation ..... 14

CONFERENCE PROGRAM

Day One ..... 16

Day Two ..... 18

Day Three ..... 19

Day Four ..... 20

ABSTRACTS

Day One ..... 22

Day Two ..... 26

Day Three ..... 28

Day Four ..... 30



## Message from the Conference Chairman

### **Prof. Ibrahim Galadari**

Secretary-General of GCC League of Dermatology, Secretary-General of Arab Academy of Dermatology & Aesthetics, President of Arab Board and Chairman of the Dubai Derma Conference

It is with great pleasure that I extend a heartfelt welcome to all attendees to the 23<sup>rd</sup> Dubai World Dermatology & Laser Conference & Exhibition, set to be held from March 5<sup>th</sup> to March 7<sup>th</sup>, 2024, at the prestigious Dubai World Trade Centre (DWTC).

In the realm of dermatology, Dubai has continuously embraced cutting-edge technologies to address the evolving needs and expectations of our community while simultaneously aspiring to establish itself as a global leader in the events and entertainment industry. This commitment is exemplified through the hosting of pioneering mega-events in the region.

Dubai Derma is proudly organized by esteemed scientific institutions, notably the Arab Academy of Dermatology and Aesthetics (AADA), in collaboration with the GCC League of Dermatology and the Pan-Arab League. As a distinguished member of the International League of Dermatology Society (ILDS), AADA ensures that our scientific program is accredited by these esteemed organizations.

Dubai Derma assembles distinguished speakers from across the globe, offering insights into a diverse range of topics shaping the field of dermatology. Our comprehensive scientific program encompasses a four-day pre-conference course, conference sessions, workshops, and live demonstrations, spotlighting innovative cosmetic and dermatological procedures.

This conference serves as a dynamic platform for dermatology professionals worldwide to enrich their knowledge, explore groundbreaking advancements in dermatology and technology, and cultivate meaningful connections.

I eagerly anticipate greeting all of you at the upcoming Dubai Derma edition!



## Message from the Executive Chairman

**H.E. Amb. Dr. Abdulsalam AlMadani**

Executive Chairman of Dubai Derma

It is my pleasure to welcome you to the 23rd edition of the Dubai World Dermatology and Laser Conference and Exhibition – Dubai Derma 2024! The leading gathering in the Middle East, North Africa, and the Indian Subcontinent, focusing on dermatology, skincare, and laser technologies.

This event celebrates innovation and expertise, allowing you to explore the expansive 25,146 sqm exhibition area dedicated to shaping the future of aesthetics and skincare. There's much to discover, with over 400 exhibitors showcasing 1,500 international aesthetic, anti-aging, and skincare brands and laser technologies.

Dubai Derma boasts a program featuring 301 speakers, including specialists, industry experts, and skincare physicians from 112 countries, all eager to share their knowledge and the latest developments in medical technology and skincare treatment across 51 sessions and 334 lectures. Attendees can actively participate in discussions, attend insightful courses, and join enlightening lectures tailored to meet the evolving needs of patients.

Your active participation in scientific sessions and practical learning contributes to the advancement of the profession and allows you to gain valuable insights into the latest developments in skincare science and anti-aging breakthroughs. Explore a wealth of resources, including 69 case studies, 30 professional poster presentations, and insights from 16 participating scientific international affiliations. Engage in 11 industry partner sessions, 53 workshops (including 32 practical workshops), and 13 live clinical sessions designed to deepen your understanding and inform you about industry trends and advancements.

We express our sincere thanks to our partners, esteemed dermatology associations, generous sponsors, distinguished exhibitors, and prominent health authorities for their unwavering support. Your presence enhances this gathering, and we appreciate your invaluable contributions to the event.

Looking forward to welcoming you at Dubai Derma 2024, held from March 5 to 7, 2024, at the prestigious Dubai World Trade Center (DWTC).

**H.E. Amb. Dr. Abdulsalam AlMadani**  
Executive Chairman of Dubai Derma



## Speech from the AADA President

### **Abdul Wahab Al Fouzan MD**

Senior Consultant of Dermatology & Venereology  
President of Arab Academy of Dermatology and Aesthetics  
President of Scientific Council of Dermatology & Venereology in the Arab Board  
of Medical Specialization

**Prof. Ibrahim Galadari, Secretary-General of GCC League of Dermatology, Secretary-General of Arab Academy of Dermatology & Aesthetics, President of Arab Board and Chairman of the Dubai Derma Conference**

**His Excellency Ambassador Dr. Abdulsalam AlMadani, PAM Roving Ambassador for the GCC Region, Executive Chairman of Dubai Derma**

Ladies and Gentlemen,

We gather today for the 23rd edition of the Dubai World Dermatology and Laser Conference and Exhibition - Dubai Derma 2024.

Before proceeding further, I want to express our sincere appreciation on behalf of all attendees. Our heartfelt thanks go to the Dubai Health Authority for their generous support of this conference. Their commitment to promoting human health and fostering the endeavors of medical professionals, researchers, and scientists is commendable. Their support plays a pivotal role in advancing healthcare services, contributing significantly to the enhancement and progress of the medical field.

This well-known annual medical conference, centered on dermatology, skin surgery, and laser treatments and hosted in Dubai, unites an esteemed assembly of consultant doctors and specialists. Participants come from the Gulf Cooperation Council countries and Arab nations as well as from the continents of America, Europe, and Asia. Incorporating four lecture halls within a single conference is a notable scientific accomplishment, offering doctors at all levels, including trainees, specialists, and consultants, the opportunity to engage, attend, and gather insights from these enriching lectures.

Let us not overlook the significance of the pre-conference workshops and training sessions. These sessions are intensive courses covering various dermatology specialties such as pathology, skin plastic surgery, and laser treatments.

Upon reviewing the conference's scientific program, many papers and research contributions emerge. The focus is on the latest advancements in laser treatment, particularly within skin surgery and the management of conditions like psoriasis, acne, and bullous diseases, as well as the treatment of aging symptoms, skin tumors, cancerous skin, and skin allergies. Additionally, attention is given to treating pigmentation, hair loss, alopecia, hereditary skin diseases, and infectious skin diseases.

The conference activities encompass a substantial number of workshops addressing the applications of lasers and strategies for addressing skin changes resulting from aging. The training courses explore specialized topics related to skin allergies, acne, pigmentation, hair loss, genetic diseases, histology, skin surgeries, and psoriasis.

It is indisputable that both the workshops and training courses offer considerable benefits, meeting the scientific and practical needs of the participating doctors.

The dedication of senior authorities in Dubai to healthcare, as witnessed through the consistent organization of conferences and seminars, has transformed it into a cultural cornerstone and an esteemed platform for all. Observed

today, the Dubai World Dermatology and Laser Conference and Exhibition, in its 23rd year, is a moment of great honor for all Arab countries.

Despite the ease of disseminating medical and therapeutic information through modern electronic channels, the significance of medical conferences remains paramount. These conferences play a crucial role in bringing together doctors, fostering closeness, and facilitating the exchange of diverse perspectives on the latest developments in our field.

This conference holds immense value for medical professionals, including recent graduates, postgraduate students, specialists, and consultants. The event encompasses training and educational programs that prove beneficial in both academic and practical aspects, aiding participants in their professional journey and preparing them for periodic exams. It also allows them to earn continuing medical education points (CME).

On behalf of both myself and the Arab Academy of Dermatology and Cosmetic Medicine, I extend a warm welcome to Dubai Derma 2024. The Academy actively engages in numerous scientific initiatives, including collaboration and participation in organizing conferences such as Dubai Derma and Sharm Derma. Its scientific endeavors extend beyond borders, encompassing the development of training courses across many Arab countries. We take pride in recognizing the Arab Academy of Dermatology and Cosmetic Medicine as a distinguished entity, holding four seats in the International League of Dermatological Societies.

In conclusion, on behalf of all attendees, I congratulate Dr. Ibrahim Galadari, Chairman of the Dubai Derma Conference, and the organizing committees for their outstanding efforts and for creating a remarkable scientific program.

A Special acknowledgment is also due to His Excellency Ambassador Dr. Abdulsalam AlMadani, PAM Roving Ambassador for the GCC Region, Executive Chairman of Dubai Derma and Chairman of INDEX Holding, and his dedicated team for their excellent organization and significant contributions to this event.

Likewise, I congratulate Dr. Hassan Galadari, Associate Professor at the College of Medicine, UAE University, Head of Scientific Committee, Dubai Derma, Secretary General of the International Society of Dermatology, and the President of the Asian Dermatology Association. His influential role in shaping this conference's scientific and practical aspects is noteworthy.

Wishing you all fruitful outcomes, success and ongoing achievements.

**Thank you,**





## Message from the Secretary General

### **Reyad Mash'al MD**

Secretary General of PAN Arab League of Dermatological Societies

**Prof. Ibrahim Galadari, Secretary-General of GCC League of Dermatology, Secretary-General of Arab Academy of Dermatology & Aesthetics, President of Arab Board and Chairman of the Dubai Derma Conference**

**His Excellency Ambassador Dr. Abdulsalam AlMadani, PAM Roving Ambassador for the GCC Region, Executive Chairman of Dubai Derma, and Chairman of INDEX Holding,**

**Dr. Abdul Wahab Al Fouzan, President of the Arab Academy of Dermatology & Aesthetics,**

**Dr. Hassan Galadari, Head of Scientific Committee, Dubai Derma, Chairman of the Asian Dermatology Association,**

**Ladies and Gentlemen,  
Esteemed Guests,**

The inauguration of the twenty-fourth edition of Dubai World Dermatology and Laser Conference and Exhibition (Dubai Derma 2024) is not merely a ceremonial observance of a typical conference. Today's inauguration of Dubai Derma commemorates a long and fruitful journey spanning years and decades of aspiration, perseverance, and accomplishment. Dubai Derma has become the leading medical conference in the Middle East, North Africa, and the Indian subcontinent, with the motto of shaping the future of dermatology and beauty.

The Dubai Derma Conference and Exhibition is a significant annual event for dermatologists from around the world to stay updated on the latest developments in diagnosing and treating skin diseases, as well as advancements in skincare and laser technologies. More than 350 lecturers from over 100 countries participate in this three-day conference held in three parallel venues, providing a platform for exchanging insights.

The conference has designated a hall for displaying clinical cases and awarding recognition for exceptional cases and research. The scientific and pharmaceutical exhibition is a significant event focusing on laser and skincare technology, with approximately 400 companies from 120 countries. More than 25,000 attendees are expected to attend the event this year.

Dubai Derma has also attracted the attention of several worldwide and regional associations to host special sessions in the conference's scientific agenda. We are pleased with this achievement, demonstrating Dubai Derma's prestigious scientific standing and motivating these organizations to participate in the event's scientific program each year. These associations include the International Society of Dermatologists, SIDEMAST, Iraqi Society of Dermatologists & Venerologists, Sham Derma, and many more.

The success story of this event is mainly attributed to Dr. Ibrahim Galadari, a pioneering figure in dermatology in the Gulf countries and the United Arab Emirates, who is the driving force behind this achievement.

On behalf of the Pan Arab League of Dermatology, I would like to thank the Government of Dubai, under the wise leadership of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, for supporting health services and medical events in Dubai. Dubai has evolved into a hub of culture and science, establishing itself as a distinguished destination for everyone.

We admire Dubai, Dr. Ibrahim, and Dr. Hassan Galadari for nominating Dubai to host the twenty-seventh conference of the International League of Dermatological Societies, **ILDS 27 Congress – Dubai 2031**. We look forward to collaborating closely to accomplish this significant milestone for Dubai and the Middle East region.

Once again, allow me to extend my heartfelt congratulations to my esteemed colleagues, Dr. Ibrahim Galadari, His Excellency Ambassador Dr. Abdulsalam AlMadani, and Dr. Hassan Galadari, for their continued successes, and express gratitude for their invaluable efforts in organizing this esteemed event with its distinguished scientific program.

May all participants experience a delightful visit to Dubai, the City of Dreams and the symbol of the future.

**Thank you.**

# Scientific Committee



**Ibrahim Galadari, MD**  
Professor of Dermatology,  
Chairman, Dubai Derma Conference



**Hassan Galadari, MD**  
Head of Scientific Committee,  
Dubai Derma

## MEMBERS



**Abdul Wahab Al Fouzan, MD**  
Kuwait



**Abdullah Al Eisa, MD**  
KSA



**Ahmed Al Wailly, MD**  
Oman



**Ahmed Al Dhaheri, MD**  
United Arab Emirates



**Ahmed Al Qahtani, MD**  
United Arab Emirates



**Ali Singel, MD**  
United Arab Emirates



**Alia Al Mualla, MD**  
United Arab Emirates



**Amani Abdulla Alfalasi, MD**  
United Arab Emirates



**Ameen Alawadhi, MD**  
Bahrain



**Andre Mattos, MD**  
Brazil



**Assem Farag, MD**  
Egypt



**Ayman AlNaeem, MD**  
United Arab Emirates



**Dhaifallah Alghowairi, MD**  
KSA



**Fahad Al Ajmi, MD**  
KSA



**Fatima Al Breiki, MD**  
United Arab Emirates



**Minal Patwardhan, MD**  
United Arab Emirates

MEMBERS



Muna Almurrawi, MD  
United Arab Emirates



Nawaf Al-Mutairi, MD  
Kuwait



Qassim Ahli, MD  
United Arab Emirates



Riad Mashal, MD  
Palestine



Salah Al Rubaie, MD  
United Arab Emirates



Shaden Abdelhadi, MD  
United Arab Emirates



Simil Ahari, MD  
United Arab Emirates



Yusra Al Ali, MD  
United Arab Emirates



Zbigniew Ruszczak, MD  
United Arab Emirates

# Organising Committee



**His Excellency Amb. Dr. Abdulsalam AlMadani**  
Executive Chairman of Dubai Derma,  
Chairman of INDEX Holding



**Eng. Anas AlMadani**  
Vice Chairman & Group CEO  
INDEX Holding



**Dr. Matios Tcholakian**  
Senior Business Development Manager  
INDEX Conferences & Exhibitions



**Andrea Barretto**  
Senior Project Manager – Head of Cluster  
INDEX Conferences & Exhibitions  
(a member of INDEX Holding)



**Vaneza Liaguno**  
Senior Project Manager  
INDEX Conferences & Exhibitions  
(a member of INDEX Holding)



**Bhagya Wijethunga**  
Event Coordinator  
INDEX Conferences & Exhibitions  
(a member of INDEX Holding)

# Accreditation

## Pre-Conference Course on Dermatology & Dermatopathology

Has been awarded by

**UAEU**

جامعة الإمارات العربية المتحدة  
United Arab Emirates University



Faculty of Medicine and Health Sciences  
United Arab Emirates University

Accreditation Number: **202312-6**

Total CME Credit Hours: **24**

**(Based on Attendance)**



## PRE-CONFERENCE COURSE ON DERMATOLOGY & DERMATOPATHOLOGY

PROGRAM & SPEAKERS

2 - 5 MARCH 2024

**DAY 1 | 2 | 3 | 4**

ABU DHABI A MEETING ROOM

# DAY ONE SATURDAY

## 2<sup>nd</sup> March 2024

### Session 1

08:30 - 09:30

#### Biologics in Dermatology: Beyond Psoriasis

Ahmed Al Waily MD | Senior Consultant Dermatologist



#### Sexually Transmitted Diseases: An Overview

Nawaf Al Mutairi MD | Professor of Dermatology



09:30 - 10:30

#### Update on The Pathogenesis and Biological Treatment of Atopic Dermatitis

Salah Al Rubaie MD | Consultant Dermatologist



10:30 - 11:00

### Coffee Break

### Session 2

11:00 - 12:00

#### Jak Inhibitors in The Management of Moderate to Severe Atopic Dermatitis

Mohammed Al Rubaye MD | Dermatology Specialist



12:00 - 13:00

#### Therapeutics & New Drugs

Ameen Alawadhi MD | Consultant Dermatologist and Dermatopathologist, Head of Dermatology and Chairperson of the Internal Medicine Department



13:00 - 14:00

### Lunch Break

### Session 3

14:00 - 14:45

#### Approach to the Patient with Cutaneous Blisters

Suad Abdulrahman MD | Specialist Registrar- Dermatology



14:45 - 15:30

#### Patch Test

Jaheersha Pakran MD | Consultant Dermatologist





# DAY ONE SATURDAY

2<sup>nd</sup> March 2024

15:30 - 16:00

Coffee Break

## Session 4

16:00 - 17:00

### Cutaneous Mosaicism - An Update 2024

**Zbigniew Ruszczak MD** | Professor & Consultant of Dermatology & Allergy, Wound Management



**Shaden Abdelhadi MD** | Pediatric Dermatology Consultant



17:00 - 17:30

### The Ten-Case Spot Diagnosis Challenge

**Yusra Al Ali MD** | Consultant Dermatologist



17:30 - 18:00

### Update in Acne

**Ibrahim Galadari MD** | Professor of Dermatology



# DAY TWO SUNDAY

## 3<sup>rd</sup> March 2024

### Session 1

08:30 - 10:30

#### Difficult Clinical Dermatology Cases

Hazem Seif El Nasr MD | Professor of Dermatology



10:30 - 11:00

### Coffee Break

### Session 2

11:00 - 12:00

#### Difficult Clinical Dermatology Cases

Hazem Seif El Nasr MD | Professor of Dermatology



12:00 - 13:00

#### Dermoscopy: A Diagnostic Tricks on Examination of Papulosequamous Skin Diseases

Dooha Alhamdi MD | Assistant Professor of Dermatology



13:00 - 14:00

### Lunch Break

### Session 3

14:00 - 15:30

#### 1. Golden Rules in Dermatological Practice 2. Interesting Clinical Cases; Challenges in Diagnosis and Treatment 3. Syphilis; Hints and Keys for Clinical Practice

Khalil Alhamdi MD | Professor of Dermatology and Consultant Dermatologist



15:30 - 16:00

### Coffee Break

### Session 4

16:00 - 17:00

#### Genodermatosis

Monira El Waseef MD | Fellowship trainer



17:00 - 18:00

#### Lymphomas and Sarcoidosis as a Great Imitator

Nadia Abdelwadood MD | Consultant of Dermatology and Sexually Transmitted Infection



# DAY THREE MONDAY

4<sup>th</sup> March 2024

## Session 1

08:30 - 10:30

1. Epidermal Tumors
2. Granulomatous Dermatitis
3. Quiz

Mohamed Khaled MD | Professor of Dermatology and Dermatopathology



10:30 - 11:00

Coffee Break

## Session 2

11:00 - 13:00

1. Applied Trichology & Trichoscopy
2. JAK inhibitors
3. Atopic Dermatitis: Cases from My Clinic
4. Emergence of Recalcitrant Dermatophytosis in Egypt
5. Clinicopathological Correlation: 100 Interesting Cases from My Clinic

Assem Farag MD | Professor of Dermatology



13:00 - 14:00

Lunch Break

## Session 3

14:00 - 15:30

1. Neuroimmune Axis of Itch
2. Prurigo Nodularis

Jacek C. Szepietowski MD | Chair of the Department of Dermatology, Venereology and Allergology



15:30 - 16:00

Coffee Break

## Session 4

16:00 - 18:00

1. Interface Dermatitis
2. Bullous Diseases
3. Panniculitis

Mohamed Khaled MD | Professor of Dermatology and Dermatopathology



DAY FOUR TUESDAY

5<sup>th</sup> March 2024

Session 1

08:30 - 10:30

1. Dermoscopy Cutaneous Malignancy
2. Dermoscopy of Papulosquamous Disorders
- Manal Bosseila MD | Professor of Dermatology



10:30 - 11:00

Coffee Break

Session 2

11:00 - 13:00

1. Trichoscopy of Common Hair Disorders
2. Quiz
- Manal Bosseila MD | Professor of Dermatology



13:00 - 14:00

Lunch Break

Session 3

14:00 - 15:30

- Sexually Transmitted Infections:
1. Dermatologic Manifestations of HIV/AIDS
2. BALANITIS
3. Genital Ulcer Disease
- Mohammed El Banhawy MD | Senior Consultant Dermatologist



15:30 - 16:00

Coffee Break

Session 4

16:00 - 18:00

- Dermatologic Therapy:
1. Lactation and Dermatologic Drugs Safety
2. Optimizing Methotrexate in Psoriasis Treatment
3. Oral Antihistamines
4. Oral Therapy of Melasma
- Mohammed El Banhawy MD | Senior Consultant Dermatologist





# ABSTRACTS

2 - 5 MARCH 2024

**DAY 1 | 2 | 3 | 4**  
ABU DHABI A MEETING ROOM

# DAY ONE SATURDAY

## 2<sup>nd</sup> March 2024

### Session 1

**08:30 - 09:30**

#### **Biologics in Dermatology: Beyond Psoriasis**

**Ahmed Al Waily MD** | Senior Consultant Dermatologist

Recent advances in the understanding of pathogenesis of inflammatory dermatoses at molecular, have ushered in biologic therapies in various dermatologic diseases. The number of currently available biological agents in dermatology is growing with new developments every passing day.

Biologics are the molecules that target specific proteins implicated in immune-mediated disease. These can be broadly classified into three main groups: monoclonal antibodies, fusion proteins, and cytokines. The use of biologic in dermatology started with psoriasis around 3 decades ago, and it continues to be the most common dermatoses targeted with biologic agents. However, in recent past the use of biologics has spilled over to various other dermatoses. Although, most of these indications still remain as "Off Label use". FDA has very recently approved some of these agents for use in dermatoses other than psoriasis. They have been used for neutrophilic dermatoses (eg, aphthous stomatitis, Behcet disease, pyoderma gangrenosum), bullous dermatoses (eg, bullous pemphigoid, pemphigus vulgaris, cicatricial pemphigoid), granulomatous dermatoses (eg, generalized granuloma annulare, sarcoidosis), auto-immune connective tissue diseases (eg, dermatomyositis, scleroderma), atopic dermatitis, chronic urticaria, vasculitis, and other disease (eg, graft-versus-host disease [GVHD], hidradenitis suppurativa, Toxic epidermal necrolysis, and pityriasis rubra pilaris. In many of these before mentioned indications, the biologics have proved to be use particularly as an alternative for patients who failed to respond to approved therapeutic options.

#### **Sexually Transmitted Diseases: An Overview**

**Nawaf Al Mutairi MD** | Professor of Dermatology

Sexually transmitted diseases (STDs) affect millions of men and women from all over the world every year. It is important to recognize that sexual contact includes more than just intercourse, and that there really is no such thing as "safe" sex. The only truly safe sex is abstinence. Recently lot of research work has been done in unraveling the pathogenesis of these group of diseases at molecular level. Also, newer drugs, including vaccines are being used/studied to control these in-factions' shall be presenting an overview of epidemiology, pathogenesis, public health implications, presentations, complications, treatment and prevention of STD's

Most of those affected happen to be either teenagers or young adults. Changing sexual partners adds to the risk of becoming infected. Early in the infection, there may be no symptoms, or symptoms may be easily confused with other illnesses. Although, most of the STD's are treatable. Viral STDs are notorious to relapse even after treatment. And, recently the bacterial STD's have started to develop resistance to conventional antibiotics. Thus, adding to the insult. However, on the positive side, vaccines against the viral organisms are under various stages of development, and also the increased awareness amongst the youth today indicate that the future seems to be promising.

# DAY ONE SATURDAY

## 2<sup>nd</sup> March 2024

**09:30 - 10:30**

### Update on The Pathogenesis and Biological Treatment of Atopic Dermatitis

**Salah Al Rubaie MD** | Consultant Dermatologist

Atopic Dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent eczematous lesions and intense itching.

The prevalence of Atopic Dermatitis has shown a worldwide increase in the past 30-40 years; and effect around 15-30% of children and 2-10% of adults.

The pathogenesis of AD is complex is due to interplay of strong genetic predisposition; epidermal barrier dysfunction; immune dysregulation and dysbiosis of microbial colonization are believed to drive cutaneous inflammation of AD.

Eventhough most of the patients respond satisfactory to topical anti-inflammatory drugs, aboiut 10-15% require one or more systemic treatments to achieve good control of the disease.

The updated knowledge in the immunopathogenesis of AD has allowed the development of innovative and targeted therapies, such as Biologic Agents targeting interleukin IL4; IL13 and JAK/STAT inhibitors. Other potential therapeutic agents for AD include agents targeting the T helper, Th22 and Th17/ IL23 pathway.

## Session 2

**11:00 - 12:00**

### Jak Inhibitors in The Management of Moderate to Severe Atopic Dermatitis

**Mohammed Al Rubaye MD** | Dermatologist

Atopic Dermatitis (AD) is a common and persistent inflammatory skin condition that most often presents in young infants (1).

12.3 % of children and teenagers aged 17 years and younger in the United Kingdom are reported to be affected by AD and this is more than double the prevalence of adults aged 18 to 74 years (2).

The pathogenesis of AD is complex and thought to be the result of an interaction of genetic and environmental variables, immunological dysfunction, dysbiosis of microbial colonization, and failure of the epidermal barrier (1, 3). Loss of function mutations in the FLG gene contribute to the epidermal barrier failure as this gene encodes for pro-filaggrin, which is an important protein in normal skin barrier formation through its degradation to filaggrin. This results in increased trans epidermal water loss (TEWL) and unwanted entry of various microbes and allergens that drive a type 2 helper (Th2) immunological response. IL-4 and IL-13 are amongst the cytokines that are increased because of this response and these cytokines can bind to their receptors and result in phosphorylation of the respective JAK signal, followed by phosphorylation of the respective STAT signal which will then separate from its receptor, dimerize, and move towards the cell nucleus where it impacts gene transcription towards producing more inflammatory cytokines (4).

Most patients with AD are controlled with topical therapy however some require systemic therapy such as Azathioprine or Mycophenolate mofetil.

# DAY ONE SATURDAY

## 2<sup>nd</sup> March 2024

More recently we have been able to provide patients with biological therapies with subcutaneous dupilumab which targets IL-4RA $\alpha$  being the go-to medication (5). Oral JAK inhibitors offer an alternative to Dupilumab in patients who are not candidates such as those with severe conjunctivitis or those who have needle phobias.

JAK inhibitors (topical or oral) are effective in treating AD as they block the JAK-STAT signalling pathway which is known to influence gene transcription and is known to regulate the inflammatory cytokines associated with AD, especially those associated with the Th2 immunological response (6). Multiple RCT's have demonstrated that oral JAK inhibitors are effective in the management of moderate to severe AD especially when compared to placebo and some studies have demonstrated that they are more effective than subcutaneous dupilumab (7).

**12:00 - 13:00**

### Therapeutics & New Drugs

**Ameen Alawadhi MD** | Consultant Dermatologist and Dermatopathologist, Head of Dermatology and Chairperson of the Internal Medicine Department

The talk will focus on updates in treating hair disorders. It will cover both scarring and non-scarring forms of Alopecia. We will also review diagnostics of these disorders.

## Session 3

**14:00 - 14:45**

### Approach to the Patient with Cutaneous Blisters

**Suad Abdulrahman MD** | Specialist Registrar- Dermatology

Blistering (bullous) diseases are a heterogeneous group of dermatological disorders. These are worldwide common disorders. In most cases the blisters (vesicles and bullae) are due to a primary disease e.g. pemphigus. As a secondary phenomenon it also occurs in a number of unrelated conditions. Five principal ways can result in blister formation namely: genetic derangement, physical, immunological

and inflammatory damage and drug reaction. Of these, immunological reaction accounts for most of the dermatological diseases producing blisters. In many cases, bullous diseases cannot be differentiated

clinically and needs the help of histopathological examination and immunofluorescence study. Sometimes examination of blister fluid can be used. Routine histological examination can help in the diagnosis of most of the blistering cases according to location and morphology of blisters. Most immune mediated blistering diseases can be defined on the basis of both direct and indirect immunofluorescence findings, and the pattern obtained is often diagnostic.

Cutaneous blisters occur in a wide variety of clinical settings, including autoimmune disorders, drug reactions, infections, genetic disorders, and physical injury. The ability to narrow the differential diagnosis for patients with blistering skin lesions is essential for the prompt recognition of life-threatening disorders and the appropriate management of other blistering diseases.

The clinical approach to the diagnosis of disorders that present with cutaneous blisters and a summary of common investigative tests used to assist with diagnosis.



# DAY ONE SATURDAY

2<sup>nd</sup> March 2024

**14:45 - 15:30**

## Patch Test

**Jaheersha Pakran MD** | Consultant Dermatologist

Patch test is gold standard of detecting allergic contact dermatitis.

Patch testing is an essential investigation to identify specific allergens in allergic contact dermatitis (ACD) or, in some cases, to make the diagnosis of ACD. Patch testing is based upon the principle that in sensitized individuals, primed antigen-specific T lymphocytes of the Th1 phenotype circulate throughout the body and are able to recreate a delayed-type hypersensitivity reaction when nonirritating concentrations of the antigen are applied to normal skin.

## Session 4

**16:00 - 17:00**

## Cutaneous Mosaicism - An Update 2024

**Zbigniew Ruszczak MD** | Professor & Consultant of Dermatology & Allergy, Wound Management

**Shaden Abdelhadi MD** | Pediatric Dermatology Consultant

**17:00 - 17:30**

## The Ten-Case Spot Diagnosis Challenge

**Yusra Al Ali MD** | Consultant Dermatologist

In our daily practice, we encounter a variety of dermatological conditions, and in many times, some diagnoses are overlooked. It is of vital importance to know different presentations of common and uncommon dermatology conditions; this will ultimately enable dermatologists to provide the best evaluation and assessment, subsequently complementing it with a perfect management plan.

Nevertheless, diagnosing critical conditions is crucial and lifesaving if done at the correct time.

In this lecture, I will share some interesting cases from our daily practice in inpatient and outpatient facilities.

I am sure that this 10-case challenge will help attendees to have a different insight and curiosity into Dermatology practice.

**17:30 - 18:00**

## Update in Acne

**Ibrahim Galadari MD** | Professor of Dermatology

To review current knowledge on how patients with acne experience stigmatization, as well as on its associations with clinical and psychosocial characteristics of the disease. A better understanding of these may help dermatologists improve screening and management for the benefit of Acne patients.

# DAY TWO SUNDAY

## 3<sup>rd</sup> March 2024

### Session 1

**08:30 – 12:00**

#### Difficult Clinical Dermatology Cases

**Hazem Seif El Nasr MD** | Professor of Dermatology

A wide spectrum of difficult Dermatology clinical cases will be discussed.

### Session 2

**12:00 – 13:00**

#### Dermoscopy: A Diagnostic Tricks on Examination of Papulosequamous Skin Diseases

**Dooha Alhamdi MD** | Assistant Professor of Dermatology

papulosequamous skin diseases are common in dermatological practice. In some times the clinical features are not so clear and misdiagnosed because they either atypical or modified by treatment at time of presentation. The diagnostic aid like histopathological examination is not always easily done particularly when the lesions at cosmetically critical site as the face. Dermoscopy is used widely now in dermatology. A diagnostic tricks and clinical keys will be demonstrated in this lecture.

### Session 3

**14:00 – 15:30**

#### Golden Rules in Dermatological Practice

**Khalil Alhamdi MD** | Professor of Dermatology and Consultant Dermatologist

in daily clinical practice one face different problems. sharing experiences with board candidates and other interested residents with experts increase their orientation and improving experiences which cannot be taught from literatures and books.

#### Interesting Clinical Cases; Challenges in Diagnosis and Treatment

**Khalil Alhamdi MD** | Professor of Dermatology and Consultant Dermatologist

In daily clinical practice and an increasing number of problematic cases may be seen which is either a topical in presentation, site evolved, or age. In this study an interesting case will be presented.

#### Syphilis; Hints and Keys for Clinical Practice

**Khalil Alhamdi MD** | Professor of Dermatology and Consultant Dermatologist

Syphilis is still present but it may be mis diagnose overlooked as it mimic a wide range of skin diseases so creating a clinical and social problems in this lecture a number of hints will be given for diagnose and keys for management

### Session 4

**16:00 – 17:00**

#### Genodermatosis

**Monira El Waseef MD** | Fellowship trainer

Different cases of Ichthyosis, some syndromic ichthyosis, Neurofibromatosis, tuberous sclerosis, palmoplantar keratoderma and Epidermolysis bullosa

# DAY TWO SUNDAY

3<sup>rd</sup> March 2024

**17:00 - 18:00**

## **Lymphomas and Sarcoidosis as a Great Imitator**

**Nadia Abdelwadood MD** | Consultant of Dermatology and Sexually Transmitted Infection

Practical Approach to diagnosis of different cases of lymphoma

Different cases of sarcoidosis with clinicopathological correlation, as sarcoidosis is great imitator, don't miss and keep in mind.

# DAY THREE MONDAY

4<sup>th</sup> March 2024

## Session 1

**08:30 - 10:30**

### **Epidermal Tumors & Granulomatous Dermatitis & Quiz**

**Mohamed Khaled MD** | Professor of Dermatology and Dermatopathology

Dermatopathology of the skin disease is very essential and integral science to understand and diagnose different skin diseases. It is considered one of the most important items in studying dermatology. No qualification of dermatology without studying and passing exams in dermatopathology. In this course of dermatopathology, we will study different inflammatory and neoplastic dermatologic diseases, including epidermal tumors, either benign or malignant, granulomatous diseases, interface dermatitis, bullous dermatoses and panniculitis. This presentation and detailed discussions will try to cover as much as possible the diseases under these titles in algorithmic approach with regard to the clinicopathological correlation. The goal is to reach the diagnosis in the simplest way taking into consideration the differential diagnoses and the imitators of each disease. Of course, we will concentrate on the tips and tricks for the final exams in dermatology at different levels.

## Session 2

**11:00 - 13:00**

### **1. Applied Trichology & Trichoscopy**

### **2. JAK inhibitors**

### **3. Atopic Dermatitis: Cases from My Clinic**

### **4. Emergence of Recalcitrant Dermatophytosis in Egypt**

### **5. Clinicopathological Correlation: 100 Interesting Cases from My Clinic**

**Assem Farag MD** | Professor of Dermatology

## Session 3

**14:00 - 15:30**

### **Neuroimmune Axis of Itch**

**Jacek C. Szepietowski MD** | Chair of the Department of Dermatology, Venereology and Allergology

Itch is defined as an unpleasant sensation leading to scratching. It is a common phenomenon in dermatology, but itch is present in numerous systemic diseases, like chronic kidney disease, hepatic and hematological disturbances as well in neurological and psychiatric conditions. The pathogenesis of itch is complex and include several factors. Recent data suggest that neuro-immune axis plays a crucial role both in creation and exacerbation of itch sensation. Activated Th2 T cells release IL- 4, IL-13 binding to the IL-4R leading to sensitization and direct stimulation of sensory neurons, proliferation of Th2 cells, migration of lymphocytes to tissues, survival of B cells, disruption of the cutaneous barrier. Activated Th2 cells, macrophages, basophils and eosinophils release also IL-31, which cause itch by binding to the IL-31R and OSMR located on keratinocytes, dermal immune cells and sensory neurons within the epidermis and dermis. Also, epidermal keratinocytes are a source of "alarmins" (epithelial derived cytokines) that trigger a Th2 immune response and include TSLP and IL-33. TSLP binds to the Thymic Stromal Lymphopoietin Receptor (TSLPR) located on sensory neurons. IL-33 binds to the ST2 receptor and causes release of IL-13 from Th2 cells, direct stimulation of sensory neurons, and also plays a role in lymphocyte chemotaxis to

# DAY THREE MONDAY

4<sup>th</sup> March 2024

affected areas. One can also put attention to recently discovered periostin released by fibroblasts in the complex pathogenesis of itch. In conclusion, synergistic neural- and immune-mediated mechanism are of importance in contemporary knowledge on itch complex pathogenesis.

## Prurigo Nodularis

**Jacek C. Szepietowski MD** | Chair of the Department of Dermatology, Venereology and Allergology

Nodular prurigo is a condition characterized by chronic itch, a prolonged scratching behaviour and the presence of pruriginous nodules. The term prurigo has been used for many decades in dermatology without clear definition, and currently used terminology of prurigo is inconsistent and confusing. As a group of European experts, we proposed new classification of chronic prurigo based on various clinical manifestations. According to this classification chronic prurigo is an umbrella term for the following clinical types of the disease: nodular, papular, plaque, umbilicated and linear. The treatment of prurigo is a challenge for both clinicians and patients. New developments in the field, including usage of nebolizumab (anti-IL31R antibody) as well as nalbuphine, may be beneficial for the chronic prurigo patients. Nodular prurigo has severe psychosocial consequences. This should be taken into consideration in the holistic approach to this group of itchy patients.

## Session 4

**16:00 - 18:00**

### 1. Interface Dermatitis

### 2. Bullous Diseases

### 3. Panniculitis

**Mohamed Khaled MD** | Professor of Dermatology and Dermatopathology

In this course of dermatopathology, we will study different inflammatory and neoplastic dermatologic diseases, including epidermal tumors, either benign or malignant, granulomatous diseases, interface dermatitis, bullous dermatoses and panniculitis. This presentation and detailed discussions will try to cover as much as possible the diseases under these titles in algorithmic approach with regard to the clinicopathological correlation. The goal is to reach the diagnosis in the simplest way taking into consideration the differential diagnoses and the imitators of each disease. Of course, we will concentrate on the tips and tricks for the final exams in dermatology at different levels.

# DAY FOUR TUESDAY

5<sup>th</sup> March 2024

## Session 1 & 2

**08:30 - 13:00**

### **1. Dermoscopy Cutaneous Malignancy**

### **2. Dermoscopy of Papulosquamous Disorders**

### **3. Trichoscopy of Common Hair Disorders**

**Manal Bosseila MD** | Professor of Dermatology

The introduction and review of dermoscopy and trichoscopy, as well as its advantages and capabilities for diagnosing and monitoring skin lesions and hair disorders in general practice, are covered in this 4-hour session. Participants will gain a solid base of understanding regarding dermoscopy techniques, exposure to the methods of detecting structures and types of skin lesions using dermoscopy, and the capacity to comprehend the terminology used to describe skin lesions as observed using dermoscopy. This will be followed by detailed case presentations of patients with papulosquamous disorders and patients with common cutaneous malignancies. For the second part of the course there will be detailed presentation of how to evaluate hair loss, qualitatively as well as quantitatively. Followed by detailed presentation of cases with patchy as well as diffuse hair loss disorders.

## Session 3

**14:00 - 15:30**

### **Sexually Transmitted Infections: Dermatologic Manifestations of HIV/AIDS**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

Cutaneous disorders may be the initial signs of HIV related immunosuppression. Recognizing HIV related skin changes may lead to diagnosis of early HIV infection, allowing initiation of appropriate antiretroviral therapy.

### **BALANITIS**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

Balanitis is inflammation of the glans penis. Balanitis has a wide range of causes. This activity will review the risk factors, evaluation and management of balanitis

### **Genital Ulcer Disease**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

This activity will focus on the current scenarios, clinical features, laboratory diagnosis, and management of genital ulcer disease

# DAY FOUR TUESDAY

5<sup>th</sup> March 2024

## Session 4

**16:00 - 18:00**

**Dermatologic Therapy: 1. Lactation and Dermatologic Drugs Safety**  
**2. Optimizing Methotrexate in Psoriasis Treatment**  
**3. Oral Antihistamines**  
**4. Oral Therapy of Melasma**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

Dermatologists need to be familiar with the potential of medications to cause harm to the fetus or mother.

### **Optimizing Methotrexate in Psoriasis Treatment**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

At present methotrexate is indicated for the treatment of all forms of moderate or severe psoriasis including psoriatic arthritis. Therapy can be conducted on an outpatient basis, so long as recommendations concerning dosage, monitoring and safety are followed.

### **Oral Antihistamines**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

Antihistamines are a pharmaceutical class of drugs used to treat histamine mediated conditions.

This activity will review the indications, contraindications, adverse effects of antihistamines in the dermatologic practice.

### **Oral Therapy of Melasma**

**Mohammed El Banhawy MD** | Senior Consultant Dermatologist

Oral tranexamic acid is a safe and effective treatment for refractory melasma.

It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy.

Hello Tomorrow



# Find your work-life groove

From laid back to more upbeat, you'll find a range of inspirations in our Business Class. Savour gourmet cuisine, laugh through the latest comedies or socialise in the Onboard Lounge. Get in tune with the business of living.

[emirates.com](http://emirates.com)



# Download the Mobile App NOW



To Get Everything You Need to know  
About **Dubai Derma** At Your Fingertips



Download on the  
App Store



GET IT ON  
Google Play



EXPLORE IT ON  
AppGallery



#DubaiDerma



dubaiderma.com



Organized by



Supported by



# SAVE THE DATE

## Dubai Derma®

Skin Health is our Concern

24<sup>th</sup> Dubai World Dermatology and  
Laser Conference & Exhibition

**Shaping the Future of  
Dermatology & Aesthetics**

**14 – 16 APRIL 2025**

Dubai World Trade Centre

Organized by



Supported by



#DubaiDerma



dubaiderma.com